Addex Therapeutics (ADXN.SW) Licensee Completes Enrollment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression
10/29/2013 9:30:12 AM
Addex Therapeutics (SIX: ADXN), a leading
company pioneering allosteric modulation-based drug discovery and development
announced today that Janssen Research & Development, LLC, on behalf of Janssen
Pharmaceuticals, Inc., has completed enrollment of 120 patients in a
multicenter, double-blind, Phase 2 study of ADX71149 in adults with major
depressive disorder who are also suffering anxiety symptoms.
Help employers find you! Check out all the jobs and post your resume.
comments powered by